Company Overview and News

15
Weekly Insider Trading October 8, 2018

2018-10-09 seekingalpha
AIRT - Almost a straight record of purchases at ever higher prices makes this a positive trend insider play.
CWH MMAC KHC COMM AIRT ADC VECO

 
MMAC / MMA Capital Management LLC DEF 14A

2018-09-28 sec.gov
UNITED STATES SECURITIES AND EXCHAN
MMAC

 
MMAC / MMA Capital Management LLC PRE 14A

2018-09-07 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
MMAC

 
MMAC / MMA Capital Management LLC FORM 8-K (Current Report)

2018-06-26 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
MMAC

 
MMAC / MMA Capital Management LLC FORM 8-K (Current Report)

2018-06-04 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
MMAC

 
MMAC / MMA Capital Management LLC FORM 8-K (Current Report)

2018-05-25 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
MMAC

 
MMA Capital Management's (MMAC) CEO Michael Falcone on Q1 2018 Results - Earnings Call Transcript

2018-05-16 seekingalpha
MMA Capital Management, LLC (NASDAQ:MMAC) Q1 2017 Results Earnings Conference Call May 11, 2018 8:30 AM ET
MMAC

 
MMAC / MMA Capital Management LLC 10-Q (Quarterly Report)

2018-05-10 sec.gov
20180331 10Q  UNITED STATES
MMAC

 
MMAC / MMA Capital Management LLC DEFINITIVE PROXY STATEMENT

2018-04-12 sec.gov
2018 Proxy UNITED STATES
MMAC

 
MMAC / MMA Capital Management LLC DEFA14A

2018-04-12 sec.gov
DEF 14A - Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION
MMAC

 
BRIEF-MMA Capital Management Says ‍Board Authorized Co To Implement A 2018 Stock Buyback Plan During Next Open Trading Window​

2018-03-16 reuters
* MMA CAPITAL MANAGEMENT LLC - BOARD AUTHORIZED CO TO IMPLEMENT A 2018 STOCK BUYBACK PLAN DURING NEXT OPEN TRADING WINDOW
MMAC

1
MMAC / MMA Capital Management LLC 10-K (Annual Report)

2018-03-16 sec.gov - 1
20171231 10K UNITED STATES SECURITIES AND EXCHANGE COMMISSION
MMAC

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to MMAC / MMA Capital Management LLC on message board site Silicon Investor.

GCAN - GammaCan International, Inc. GCAN - GammaCan International, Inc. GCAN - GammaCan International, Inc. MultiMedia Access Corp. MMAC, teamed with SUN, MCI, others MultiMedia Access Corp. MMAC, teamed with SUN, MCI, others MultiMedia Access Corp. MMAC, teamed with SUN, MCI, others
CUSIP: 55315D105